Marijuana > Marijuana Exposure in Pediatric Populations
CE Origination Date – 04/19/17
CE Expiration Date – 04/19/21
The goal of this course is to enhance the knowledge of physicians and other healthcare providers about the health impacts of marijuana exposure among the pediatric population. By enhancing their knowledge, physicians and other healthcare providers can better assess pediatric patients who may suffer symptoms caused by marijuana exposure, provide informed guidance to their patients' caregivers, and advocate for stronger legislation to support exposure prevention.
Learning Objectives
- Describe how marijuana legislation has affected the incidence of marijuana exposures in pediatric populations.
- Recognize the basic pharmacology, pharmacokinetics, and methods of marijuana use.
- Explain marijuana urine testing.
- Describe the clinical effects of marijuana exposure in children and treatment for pediatric marijuana intoxication.
- Identify strategies to prevent unintentional pediatric exposures
Developed By
George Sam Wang, MD, FAAP
Assistant Professor of Pediatrics
Section of Emergency Medicine, Medical Toxicology
Department of Pediatrics
University of Colorado Anschutz Medical Campus, Children's Hospital Colorado
Aurora, CO
Dr. Wang, completed his pediatric residency and pediatric emergency medicine fellowship at Children's Hospital Colorado/Anschutz Medical Campus, and his medical toxicology fellowship at the Rocky Mountain Poison and Drug Center at Denver Health. He is an Assistant Professor of Pediatrics at Children's Hospital Colorado/Anschutz Medical Campus where he is a PEM and toxicology attending.
Acknowledgement: The U.S. Environmental Protection Agency (EPA) supports the PEHSU by providing partial funding to ATSDR under Inter-Agency Agreement number DW-75-95877701. Neither EPA nor ATSDR endorse the purchase of any commercial products or services mentioned in PEHSU publications.